^
Association details:
| Biomarker: | CD79B mutation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Imbruvica (ibrutinib) (BTK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study
Published date:
11/01/2020
Excerpt:
Among 21 patients with DLBCL (median age 53.5 years), 17 achieved a complete response (CR) and 4 a partial response (PR). Of the 11 subtyped patients, 9 had a CR (5/7 germinal center B-cell-like [GCB] and 4/4 non-GCB) and 2 had a PR (both GCB)….Mutation analysis (n = 19) revealed variants including CREBBP, KMT2D, LRP1B, BCL2, and TNFRSF14; only 1 CD79B and TP53 each; no CARD11 or MYD88.
Secondary therapy:
R-CHOP
DOI:
10.1016/j.ctarc.2020.100235
Trial ID:
Source:
Title:
A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression
Published date:
08/26/2020
Excerpt:
We found that CD79B-mutant Val cells were more susceptible to 10 μM ibrutinib-induced growth inhibition and apoptosis when compared with CD79B-wildtype OCI-Ly8 cells (p < 0.01); PIM1-mutant OCI-Ly8 cells also presented a better response to 40 μM AZD 1208 than PIM1-wildtype Val cells (p < 0.01) (Fig. 4b, c, and d)... These results suggest that CD79B and PIM1 mutations make DLBCL cells sensitive to BTK and pan-PIM kinase inhibitors.
DOI:
10.1186/s40364-020-00214-3
